(Q37990768)

26 August 2017

Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies (English)

1 reference

26 August 2017

1 reference

2

Ashley B Grossman

1 reference

26 August 2017

Svenja Nölting

1

1 reference

26 August 2017

1 March 2012

1 reference

26 August 2017

1 reference

26 August 2017

23

1 reference

26 August 2017

1

1 reference

26 August 2017

21-33

1 reference

https://scigraph.springernature.com/pub.10.1007/s12022-012-9199-6

26 August 2017

0 references

cites work

Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001).

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Genetic analysis of mitochondrial complex II subunits SDHD, SDHB and SDHC in paraganglioma and phaeochromocytoma susceptibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

SDHA is a tumor suppressor gene causing paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

SDH5, a gene required for flavination of succinate dehydrogenase, is mutated in paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

PHD2 mutation and congenital erythrocytosis with paraganglioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Identification of the von Hippel-Lindau disease tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Mutations in SDHC cause autosomal dominant paraganglioma, type 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Germline mutations in TMEM127 confer susceptibility to pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Pheochromocytoma: the expanding genetic differential diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Germ-line mutations in nonsyndromic pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Prevalence of SDHB, SDHC, and SDHD germline mutations in clinic patients with head and neck paragangliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Mutations of the SDHB and SDHD genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Genetic testing in pheochromocytoma or functional paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Genetic analyses of apparently sporadic pheochromocytomas: the Rotterdam experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Signaling through Ras is essential for ret oncogene-induced cell differentiation in PC12 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

TORC1 is essential for NF1-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Germline mutations of the TMEM127 gene in patients with paraganglioma of head and neck and extraadrenal abdominal sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

The Myc/Max/Mad network and the transcriptional control of cell behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

The nerve growth factor-responsive PC12 cell line does not express the Myc dimerization partner Max

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Regulation of gene expression in hepatic cells by the mammalian Target of Rapamycin (mTOR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Gene expression profiling of benign and malignant pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

A HIF1alpha regulatory loop links hypoxia and mitochondrial signals in pheochromocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Pheochromocytomas: the (pseudo)-hypoxia hypothesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Recent insights into the molecular pathogenesis of pheochromocytoma and paraganglioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

The rapamycin-derivative RAD001 (everolimus) inhibits cell viability and interacts with the Akt-mTOR-p70S6K pathway in human medullary thyroid carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Regulation of the 14-3-3-binding protein p39 by growth factors and nutrients in rat PC12 pheochromocytoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

The von Hippel-Lindau tumor suppressor gene and kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

A novel TMEM127 mutation in a patient with familial bilateral pheochromocytoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

The Warburg effect is genetically determined in inherited pheochromocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

An immunohistochemical procedure to detect patients with paraganglioma and phaeochromocytoma with germline SDHB, SDHC, or SDHD gene mutations: a retrospective and prospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

SDHB loss predicts malignancy in pheochromocytomas/sympathethic paragangliomas, but not through hypoxia signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

The PTEN-PI3K pathway: of feedbacks and cross-talks

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Phosphorylation and regulation of Raf by Akt (protein kinase B)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Evaluation of HIF-1 inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Patient with malignant paraganglioma responding to the multikinase inhibitor sunitinib malate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Sunitinib, a novel therapy for anthracycline- and cisplatin-refractory malignant pheochromocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

New targets and therapeutic approaches for endocrine malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Overexpression of the insulin-like growth factor I receptor in human pheochromocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

c-Myc Does Not Require Max for Transcriptional Activity in PC-12 Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12022-012-9199-6

Novel pheochromocytoma susceptibility loci identified by integrative genomics

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Malignant pheochromocytoma: new malignancy criteria

1 reference

12 December 2020

Oncogenic mutations of PIK3CA in human cancers

1 reference

12 December 2020

The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1alpha and vascular endothelial growth factor formation.

1 reference

12 December 2020

Negative regulation of the serine/threonine kinase B-Raf by Akt

1 reference

12 December 2020

Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma

1 reference

12 December 2020

Treatment of malignant pheochromocytoma

1 reference

12 December 2020

Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1alpha.

1 reference

12 December 2020

Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer

1 reference

12 December 2020

Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma

1 reference

12 December 2020

Changing paradigms in the treatment of malignant pheochromocytoma

1 reference

12 December 2020

Von Hippel-Lindau gene alterations in sporadic benign and malignant pheochromocytomas

1 reference

12 December 2020

Genetic mutation screening in an italian cohort of nonsyndromic pheochromocytoma/paraganglioma patients

1 reference

12 December 2020

Familial pheochromocytoma.

1 reference

12 December 2020

Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells

1 reference

12 December 2020

Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy

1 reference

12 December 2020

Pheochromocytomas in Nf1 knockout mice express a neural progenitor gene expression profile

1 reference

12 December 2020

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

1 reference

12 December 2020

10.1007/S12022-012-9199-6

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22391976